Robert Koch Institute, Association of Population-Based Cancer Registries in Germany. Cancer in Germany 2009/2010. 2014.
Jin H, Pinheiro PS, Callahan KE, Altekruse SF. Examining the gastric cancer survival gap between Asians and whites in the United States. Gastric Cancer. 2017;20:573–82.
Article
Google Scholar
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
CAS
Article
Google Scholar
Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative therapy of oesophagogastric adenocarcinoma: mainstay and future directions. Gastroenterol Res Pract. 2017;2017:5651903.
Article
Google Scholar
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;110:189–94.
Article
Google Scholar
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: gastric cancer. Version 2. 2018. https://www.nccn.org/. Accessed 28 Nov 2018.
European Medicines Agency. Teysuno® (S-1): summary of product characteristics. https://www.ema.europa.eu/documents/product-information/teysuno-epar-product-information_en.pdf. Accessed 28 Nov 2018.
Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/Infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study. J Clin Oncol. 2010;28:1547–53.
CAS
Article
Google Scholar
Ter Veer E, Ngai LL, Valkenhoef GV, Mohammad NH, Anderegg MCJ, van Oijen MGH, van Laarhoven HWM. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: a network meta-analysis. Sci Rep. 2017;7:7142.
Article
Google Scholar
Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.
CAS
Article
Google Scholar
Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005;23:6957–65.
CAS
Article
Google Scholar
Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van Alphen RJ, Polee MB, Muller EW, van der Velden AMT, van Voorthuizen T, Koopman M, Mol L, van Werkhoven E, Punt CJA. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017;28:1288–93.
CAS
Article
Google Scholar
Kwakman JJM, Baars A, Boot H, Pruijt JFM, Winther SB, Pfeiffer P, Punt CJA. Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in Western cancer patients. Acta Oncol. 2017;56:1023–6.
CAS
Article
Google Scholar
Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer. 2017;76:93–9.
CAS
Article
Google Scholar
Kwakman JJM, Baars A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer. 2017;81:130–4.
CAS
Article
Google Scholar
Franck C, Malfertheiner P, Venerito M. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. BMJ Case Rep. 2017;2017. pii: bcr-2016-219162.
Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 28 Nov 2018.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
Article
Google Scholar
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O’Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.
CAS
Article
Google Scholar
Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol. 2017;35:3575–81.
CAS
Article
Google Scholar
Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW. Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs R D. 2017;17:117–24.
CAS
Article
Google Scholar
Franck C, Canbay A, Malfertheiner P, Venerito M. Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: two case reports and review of the literature. Mol Clin Oncol. 2017;7:1069–72.
PubMed
PubMed Central
Google Scholar
Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD). Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2018;50:768–79.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v38–49.
Lokich J. What is the “best” platinum: cisplatin, carboplatin, or oxaliplatin? Cancer Invest. 2001;19:756–60.
CAS
Article
Google Scholar